Patents by Inventor Bum-Joon Kim

Bum-Joon Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11512317
    Abstract: Provided is a recombinant BCG employing a pMyong2 vector system to express HIV-1 p24 and a use thereof as a HIV-1 vaccine. rBCG-pMyong2-p24, which is a pMyong2 vector system, was found to induce the upregulation of HIV-1 p24 gag expression in rBCG and infected antigen-presenting cells (APC) and to induce improved p24-specific immune responses in vaccinated mice, compared to rBCG-pAL-p24 in a pAL5000 derived vector system. rBCG-pMyong2-p24 was identified to exhibit a higher p24-specific Ab production level than rSmeg-pMyong2-p24 in the same pMyong2 vector system. Therefore, the recombinant BCG employing rBCG-pMyong2-p24 to express HIV-1 p24 according to the present invention is identified to elicit enhanced immune responses to HIV-1 infection in mouse model systems and thus can be expected to be used as a prime vaccine in the heterologous prime-boost vaccination strategy against HIV-1 infection.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: November 29, 2022
    Assignee: SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION
    Inventors: Bum-Joon Kim, Byoung-Jun Kim, Bo-Ram Kim
  • Patent number: 11485711
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: November 1, 2022
    Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
  • Publication number: 20220331407
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: June 8, 2022
    Publication date: October 20, 2022
    Inventors: Sang Jae KIM, Kyung Hee KIM, Kyu-Yong LEE, Seong-Ho KOH, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Bum Joon KIM
  • Patent number: 11447469
    Abstract: The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: September 20, 2022
    Assignees: Korea Research Institute of Chemical Technology, Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Sung Youn Chang, Hyuk Lee, Ki Young Kim, Bum Tae Kim, Sung Soo Kim, Seong Hwan Kim, Hwan Jung Lim, Jung Nyoung Heo, Sang Joon Shin, Sang Youn Park
  • Patent number: 11369665
    Abstract: A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: June 28, 2022
    Assignee: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Patent number: 11331350
    Abstract: The present invention relates to an anti-cancer regulatory response and immunotherapy by Mycobacterium paragordonae (M. paragordonae). Mycobacterium paragordonae according to an aspect has cancer cytotoxicity mediated by natural killer cells or T cells as well as cytotoxicity against cancer cells, and inhibits activation of cancer cytotoxicity regulatory T cells of macrophages or dendritic cells to induce an immune response, thereby inhibiting tumor formation and thus being useful for a cancer immunotherapeutic agent.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: May 17, 2022
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Bum-Joon Kim, So-Young Lee
  • Publication number: 20220109162
    Abstract: Disclosed are an electrode including a polymer matrix and a catalyst including metal nanoparticles and a conductive polymer shell and, a method of preparing the same. According to various exemplary embodiments of the present invention, various hybrid nano-composites may be formed by a combination of other conductive polymers than P3HT with metal nanoparticles. For example, the method may include selectively disposing metal nanoparticles to a surface modified conductive polymer including a block copolymer of two or more types of conductive polymers.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Inventors: You Jung Song, Hong Seok Yun, Jin Seong Kim, Bum Joon Kim, Young Kwon Kim
  • Patent number: 11233246
    Abstract: Disclosed are an electrode including a polymer matrix and a catalyst including metal nanoparticles and a conductive polymer shell and, a method of preparing the same. According to various exemplary embodiments of the present invention, various hybrid nano-composites may be formed by a combination of other conductive polymers than P3HT with metal nanoparticles. For example, the method may include selectively disposing metal nanoparticles to a surface modified conductive polymer including a block copolymer of two or more types of conductive polymers.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: January 25, 2022
    Assignees: Hyundai Motor Company, Kia Motors Corporation, Korea Advanced Institute of Science and Technology
    Inventors: You Jung Song, Hong Seok Yun, Jin Seong Kim, Bum Joon Kim, Young Kwon Kim
  • Publication number: 20210388328
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: July 30, 2021
    Publication date: December 16, 2021
    Inventors: Sang Jae KIM, Kyung Hee KIM, Kyu-Yong LEE, Seong-Ho KOH, Bum Joon KIM, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Hwain JANG, Jung Soon HA
  • Patent number: 11098294
    Abstract: The present invention relates to methods of treating or preventing inflammation with a peptide having anti-inflammatory activity, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 101. According to the present invention, the peptide of SEQ ID NO: 101 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the method comprising administration of the peptide of this invention can be used in anti-inflammatory pharmaceutical or cosmetic applications, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: August 24, 2021
    Assignee: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Bum Joon Kim, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Hwain Jang, Jung Soon Ha
  • Publication number: 20210228690
    Abstract: A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: October 26, 2020
    Publication date: July 29, 2021
    Applicant: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae KIM, Kyung Hee KIM, Kyu-Yong LEE, Seong-Ho KOH, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Bum Joon KIM
  • Publication number: 20210222179
    Abstract: Provided is a recombinant BCG employing a pMyong2 vector system to express HIV-1 p24 and a use thereof as a HIV-1 vaccine. rBCG-pMyong2-p24, which is a pMyong2 vector system, was found to induce the upregulation of HIV-1 p24 gag expression in rBCG and infected antigen-presenting cells (APC) and to induce improved p24-specific immune responses in vaccinated mice, compared to rBCG-pAL-p24 in a pAL5000 derived vector system. rBCG-pMyong2-p24 was identified to exhibit a higher p24-specific Ab production level than rSmeg-pMyong2-p24 in the same pMyong2 vector system. Therefore, the recombinant BCG employing rBCG-pMyong2-p24 to express HIV-1 p24 according to the present invention is identified to elicit enhanced immune responses to HIV-1 infection in mouse model systems and thus can be expected to be used as a prime vaccine in the heterologous prime-boost vaccination strategy against HIV-1 infection.
    Type: Application
    Filed: March 27, 2019
    Publication date: July 22, 2021
    Applicant: SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION
    Inventors: Bum-Joon KIM, Byoung-Jun KIM, Bo-Ram KIM
  • Patent number: 10960056
    Abstract: A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: March 30, 2021
    Assignee: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Publication number: 20210085757
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, the peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: December 4, 2020
    Publication date: March 25, 2021
    Inventors: Sang Jae KIM, Kyung Hee KIM, Kyu-Yong LEE, Seong-Ho KOH, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Bum Joon KIM
  • Publication number: 20210054029
    Abstract: A hepatitis B virus-derived polypeptide exhibits anti-viral effects not only on HIV-1 and HBV but also on all viruses by increasing the expression of type I interferon. The hepatitis B virus-derived polypeptide has a synergistic effect when co-administered with a conventional anti-viral agent. The hepatitis B virus-derived polypeptide is effectively usable in the treatment of virus-related diseases such as AIDS or liver diseases.
    Type: Application
    Filed: November 5, 2020
    Publication date: February 25, 2021
    Inventors: Bum Joon KIM, Yu Min CHOI, Hong KIM
  • Patent number: 10900963
    Abstract: The present invention is related to a parallel line biochip for multiplex diagnosis. The parallel line biochip for multiplex diagnosis includes a plurality of line strips disposed in parallel, and a well configured to immobilize the line strips. Since the parallel line biochip for multiplex diagnosis can be used to connect two or more line strips in parallel, the parallel line biochip for multiplex diagnosis has an effect of measuring various materials present in a biological test sample at the same time.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: January 26, 2021
    Inventors: Kook Jin Lim, Dong Seob Choi, Bum Joon Kim, Mi Jung Kim, Myung Sook Chung, Hye Jung Lee
  • Patent number: 10888606
    Abstract: A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 12, 2021
    Assignee: GEMVAX & KAEL CO., LTD.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Publication number: 20200323928
    Abstract: The present invention relates to an anti-cancer regulatory response and immunotherapy by Mycobacterium paragordonae (M. paragordonae). Mycobacterium paragordonae according to an aspect has cancer cytotoxicity mediated by natural killer cells or T cells as well as cytotoxicity against cancer cells, and inhibits activation of cancer cytotoxicity regulatory T cells of macrophages or dendritic cells to induce an immune response, thereby inhibiting tumor formation and thus being useful for a cancer immunotherapeutic agent.
    Type: Application
    Filed: October 26, 2018
    Publication date: October 15, 2020
    Inventors: Bum-Joon KIM, So-Young LEE
  • Publication number: 20200208127
    Abstract: The present invention relates to methods of treating or preventing inflammation with a peptide having anti-inflammatory activity, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 101. According to the present invention, the peptide of SEQ ID NO: 101 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the method comprising administration of the peptide of this invention can be used in anti-inflammatory pharmaceutical or cosmetic applications, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Applicant: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae KIM, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho KOH, Bum Joon Kim, Hyun-Hee PARK, Sung Jin HUH, Woo Jin LEE, Hwain JANG, Jung Soon HA
  • Patent number: 10659933
    Abstract: An information processing system includes a first electronic device configured to collect data, a second electronic device configured to obtain at least a portion of the data from the first electronic device and process the at least the portion of the data, and a server configured to support a sharing service that obtains the processed data from the second electronic device and posts the processed data in a designated method. The second electronic device is configured to transmit account information on at least one account joined to the sharing service to the first electronic device. The first electronic device is configured to analyze the account information to verify the at least one account, generate an object supporting posting the processed data on the sharing service, and output the object to a display of the first electronic device.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: May 19, 2020
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Seong Ook Jeong, Geun Woo Kim, Bum Joon Kim, Heum Mo Gu, Jin Mook Lim